Home / Research Reports / Pharmaceuticals
Healthcare Foresights · Market Intelligence

Global Hemorrhagic Septicemia Vaccines Market 2026 – 2035

✓ Fact-checked research▣ Report code: HF1158◷ Published: June 23, 2026▤ 220+ pages⇩ PDF, Excel
▤220+ pages
▥10+ companies
▦Base year 2025
↗Forecast 2026–2035
◎Global coverage
0.39 BillionMarket size
0.57 BillionForecast value
4.6%CAGR
GlobalCoverage
2025Base year

The global hemorrhagic septicemia (HS) vaccines market is projected to reach USD 0.39 billion in 2026 and USD 0.57 billion by 2035, growing at a 4.6% CAGR. Growth is supported by recurring disease burden in endemic livestock populations in South Asia and Sub-Saharan Africa, rising government animal health spending, and oil-adjuvant formulations that extend immunity and reduce the need for annual revaccination.

Hemorrhagic Septicemia Vaccines Market Size 2025 to 2035 (USD Billion)

Market Highlights

  • Asia Pacific held about 58% of the market in 2025 and is expected to be the fastest-growing region at roughly 5.8% CAGR through 2035.
  • Oil-adjuvant inactivated vaccines held about 47% of revenue in 2025, offering roughly 12 months of immunity per dose versus 6-9 months for alum-precipitated bacterins.
  • Live attenuated vaccines are forecast to grow at about 6.4% CAGR, supported by intranasal and oral delivery suited to mass vaccination.
  • Buffalo are more severely affected by HS than cattle, which raises per-animal vaccine revenue in key markets.
  • Government veterinary programs accounted for about 52% of 2025 revenue.

Significant Growth Factors

Government-Funded National Vaccination Programs

Government HS vaccination programs in endemic countries, especially India, are the largest structural driver of institutional procurement. India has a very large susceptible herd, and its national programs tender large dose volumes for free or low-cost delivery to smallholder farmers. Similar programs operate in Bangladesh, Myanmar, Sri Lanka, Vietnam, Thailand, the Philippines, and Indonesia.

Private Sector Investment in Commercial Farming

Commercial dairy and livestock enterprises in South and Southeast Asia are adopting systematic HS vaccination as part of biosecurity and supply-chain continuity. Vaccination costs are small relative to potential outbreak losses.

Major Advances Changing the Market

Oil-Adjuvant Vaccine Formulation Innovation

Newer oil-adjuvant systems offer better viscosity, injectability, stability, and immunogenicity than older mineral-oil formulations. Reduced dose volumes simplify mass vaccination campaigns in remote areas.

Subunit and Recombinant Vaccine Research

Research into subunit, recombinant protein, and nucleic acid vaccines aims to address the limits of whole-cell bacterins. A live attenuated aroA-deleted B:2 candidate has shown efficacy in challenge trials.

Digital Health Management and Cold Chain Technology

Digital livestock health platforms enable individual-animal tracking of vaccinations. Solar refrigerators and passive cold-chain carriers help maintain vaccine temperature in last-mile distribution.

Category Wise Insights

By Vaccine Type

Oil-adjuvant inactivated vaccines led with about 47% of 2025 revenue. Their longer immunity supports annual single-dose programs.

By Animal Type

Buffalo accounted for about 44% of 2025 revenue, higher than their share of the bovine population, due to more severe disease and higher per-animal value.

By End User

Government veterinary programs accounted for about 52% of 2025 revenue through centralized tenders covering millions of doses.

Regional Analysis

Asia-Pacific Hemorrhagic Septicemia Vaccines Market Size 2025 to 2035 (USD Billion)

Asia Pacific

Asia Pacific is expected to reach USD 0.36 billion by 2035 at a 5.8% CAGR and held about 58% of global revenue in 2025. India alone is estimated at 35-40% of global HS vaccine revenue.

Middle East and Africa

The MEA region contributed about 22% of 2025 revenue, led by Sub-Saharan Africa, endemic for the E:2 serotype.

North America and Europe

North America and Europe together account for about 15% of revenue, mainly through multinational manufacturers and regulators.

Key Developments

  • April 2024: A PmSLP3-based formulation was reported to give cross-serogroup protection against B:2 and E:2 strains in cattle.
  • January 2025: ICAR-Indian Veterinary Research Institute published a comparison of adjuvants for next-generation HS vaccines.

Meet the team

This report was prepared by our expert analysts with deep industry knowledge and hands-on research experience.

Veena Jagtap

Author · Healthcare Research Manager

A results-driven Healthcare Research Manager at Custom Market Insights, specializing in healthcare market intelligence, industry analysis, competitive benchmarking, and strategic market assessments. Experienced in managing end-to-end healthcare research projects, analyzing industry trends, evaluating competitive landscapes, and identifying emerging market opportunities across pharmaceuticals, biotechnology, medical devices, healthcare services, and life sciences. Skilled in leading research initiatives, developing customized research methodologies, and transforming complex market data into actionable business insights. With a strong analytical mindset, strategic perspective, and commitment to research excellence, I focus on delivering accurate, data-driven intelligence that empowers clients to make informed business decisions, strengthen market positioning, and achieve sustainable growth in the evolving global healthcare industry.

Table of Contents

Explore the chapters covered in the full report.

Chapter 1. Report Introduction
  • 1.1 Report Description
    • 1.1.1 Purpose of the Report
    • 1.1.2 USP & Key Offerings
  • 1.2 Key Benefits For Stakeholders
  • 1.3 Target Audience
  • 1.4 Report Scope
Chapter 2. Market Overview
  • 2.1 Market Definition & Scope
  • 2.2 Key Market Takeaways
  • 2.3 Market Snapshot
Chapter 3. Market Dynamics (DRO)
  • 3.1 Drivers
  • 3.2 Restraints
  • 3.3 Opportunities
  • 3.4 Market Trends
Chapter 4. Hemorrhagic Septicemia Vaccines Market - Market Segmentation
  • 4.1 Segment Overview
  • 4.2 Market Size & Forecast by Segment
Chapter 5. Hemorrhagic Septicemia Vaccines Market - Regional Analysis
  • 5.1 North America
  • 5.2 Europe
  • 5.3 Asia Pacific
  • 5.4 Middle East & Africa
  • 5.5 Latin America
Chapter 6. Competitive Landscape
  • 6.1 Market Share Analysis
  • 6.2 Company Benchmarking
  • 6.3 Strategic Developments
Chapter 7. Company Profiles
  • 7.1 Zoetis Inc.
  • 7.2 Merck Animal Health
  • 7.3 Boehringer Ingelheim Animal Health
  • 7.4 Elanco Animal Health
  • 7.5 Ceva Santé Animale
  • 7.6 Indian Immunologicals Limited
  • 7.7 Phibro Animal Health Corporation
  • 7.8 Brilliant Bio Pharma
  • 7.9 FATRO S.p.A.
  • 7.10 Vetoquinol S.A.
Chapter 8. Research Methodology
  • 8.1 Research Approach
  • 8.2 Data Collection & Sources
  • 8.3 Market Estimation & Forecasting
  • 8.4 Data Validation & Triangulation
Chapter 9. Standard Report Commercials & Add-Ons
Chapter 10. List Of Figures
Chapter 11. List Of Tables

Company Listing

  • Zoetis Inc.
  • Merck Animal Health
  • Boehringer Ingelheim Animal Health
  • Elanco Animal Health
  • Ceva Santé Animale
  • Indian Immunologicals Limited
  • Phibro Animal Health Corporation
  • Brilliant Bio Pharma
  • FATRO S.p.A.
  • Vetoquinol S.A.

Market Segments

Market Segmentation

Segmented by vaccine type (oil-adjuvant inactivated, aluminum hydroxide-adjuvant inactivated, live attenuated, other), animal type (cattle, buffalo, other), end user (veterinary clinics, government programs, research institutes), distribution channel, and region (North America, Europe, Asia Pacific, MEA, Latin America).

Frequently asked questions

Which region is expected to grow at the fastest CAGR?
Asia Pacific, at about 5.8% during 2026-2035, led by India and secondary markets such as Bangladesh and Myanmar.
Which region is anticipated to dominate the market?
Asia Pacific is expected to keep its dominant position, with a revenue share of around 55% during the forecast period.
What is the projected market size by the end of the forecast period?
The market is expected to reach about USD 0.57 billion by 2035 at a 4.6% CAGR from 2026.
Who are the key players in the Hemorrhagic Septicemia Vaccines market?
Major players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva, Indian Immunologicals, and Phibro, along with regional manufacturers.

Need a tailored view of this market?

Ask our analysts to adapt the scope for your priority geographies, competitive set, customer segments, or strategic questions.

Request Customisation → Request a Sample